Reston, VA (November 14, 2025)—New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
Summaries of the newly published research articles are provided below.
Comparing Two PET Scans for Spotting Significant Prostate Tumors
In this multicenter study, men with newly diagnosed intermediate- or high-risk prostate cancer received two types of PET/CT scans before surgery. Researchers evaluated how well each scan detected and pinpointed clinically significant tumors, using surgically removed tissue as the reference standard.
A Global Look at a More Accurate Scan for High-Risk Prostate Cancer
In a large international study, men with high-risk prostate cancer received a specialized PSMA PET/CT scan before treatment. Researchers compared its performance with MRI and surgical tissue analysis, examining how well it detected tumor spread and how often the scan changed decisions about whether surgery was appropriate.
Exploring Longer Use of PSMA Radiopharmaceutical Therapy
This review looks at two ways of continuing PSMA-targeted radiopharmaceutical treatment for advanced prostate cancer: either extending therapy beyond six cycles or restarting it after a break. It summarizes how these approaches are used, their safety profiles, and early signs of treatment response in carefully selected patients.
First Imaging Study of How an ALS Antisense Drug Spreads in the Body
Researchers tested a radiolabeled version of the ALS drug tofersen to see how it moves through the brain and spinal cord in animals and humans. Using SPECT/CT imaging, they observed broad central nervous system uptake and species-specific differences in how the drug distributes and clears after injection.
A New PET Tracer to Track Huntington Disease Protein Aggregates
Researchers tested a novel PET radioligand, ¹⁸F-CHDI-385, in a Huntington disease mouse model to measure harmful mutant huntingtin aggregates in the brain. The tracer showed stable behavior, clear differences between healthy and disease-model mice, and strong agreement across imaging methods, supporting its potential for noninvasive monitoring.
Visit the JNM website for the latest research, and follow our new Twitter and Facebook pages @JournalofNucMed or follow us on LinkedIn .
